Projet PurinesDX (Horizon 2020, appel à projets 2017)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

Brain disorders affect ~179 million people and their families in Europe alone, with an annual cost to the taxpayer estimated at €800 billion- a greater economic burden than cardiovascular disease and cancer combined. Despite diverse etiology, overlap in clinical symptoms and comorbidities between brain disorders suggests shared patho-mechanisms. In particular, hyperexcitible states driven by glial activation and neuroinflammation appear near ubiquitous. Targeting these mechanisms offers the potential to ameliorate symptoms and reverse disease progression across a broad span of brain disorders. Functioning as a gatekeeper to neuroinflammation and mechanistic link between neuronal hyperexcitability and glial activation, the ATP-gated, ionotropic purinergic P2X7 receptor (P2X7R) offers the most promising target for pharmacological intervention in the neuroinflammation-hyperexcitability pathway, to date. With breakthroughs in understanding P2X7R function, highly promising effects demonstrated for antagonists in models of brain disease and vast investment in P2X7R-related drug development programmes, now is the perfect time to pool resources. PurinesDX brings together global leaders in translational research in purinergic signalling, Europe’s leading clinical specialists in a broad range of brain diseases, and industrial partners specializing in drug and biomarker development. Sharing unique genetic tools, newly developed diagnostic devices and novel, selective and brain-stable P2X7R antagonists, the synergism facilitated within PurinesDX will extend to the training of an urgently needed new generation of highly skilled, innovative, creative and entrepreneurial scientists. Alongside the provision of this interdisciplinary, international and intersectoral environment, an original and high level training in state-of-the-art neuroscience will be provided, nurturing a cohort of highly competitive researchers with potential to drive a new era of neuroscience research.

Mots clés : brain diseases, inflammation, hyperexcitability, purinergic signaling, atp gated p2x7 receptor, blood biomarkers, biosensors, drug development, pre clinical animal models, clinical testing

Participants :
- Royal College of Surgeons in Ireland (Irlande) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 531349.2 €
- Epilepsiezentrum frankfurt rhein-main (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Instituto Ramón y Cajal de Investigación Sanitaria (Espagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- Affectis phamaceuticals ag (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Longboat clinical ltd (Irlande) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Warwick (Royaume-Uni) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Autonomous University of Madrid (Espagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Dr. seibt genomics gmbh (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Fundacion teofilo hernando (Espagne) — Partner, beneficiary, Recherche, subvention : 495745.92 €
- Semmelweis University (Hongrie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Janssen (Belgium) (Belgique) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ludwig-Maximilians-Universität München (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- Universidad Complutense de Madrid (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 495745.92 €
- Biomedical Research Networking Center on Neurodegenerative Diseases (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- Max Planck Society (Allemagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- Fundacion Centro De Investigacion De Enfermedades Neurologicas (Espagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- Hungarian Academy of Sciences (Hongrie) — Partner, beneficiary, Recherche, subvention : 447827.04 €
- Sarissa biomedical limited (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 546575.76 €
- Max Planck Society (Allemagne) — Partner, beneficiary, Recherche, subvention : 249216.48 €
- Magyar Agrár- és Élettudományi Egyetem (Hongrie) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- BioTalentum (Hungary) (Hongrie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 223913.52 €